- Drug Pipelines
- September 2020
- 216 pages
From €6045EUR$6,950USD£5,237GBP
- Report
- September 2020
- 200 pages
From €6045EUR$6,950USD£5,237GBP
- Drug Pipelines
- September 2020
- 120 pages
From €2175EUR$2,500USD£1,884GBP
- Drug Pipelines
- August 2020
- 1084 pages
From €1740EUR$2,000USD£1,507GBP
- Report
- August 2020
- 116 pages
From €3697EUR$4,250USD£3,203GBP
- Report
- August 2020
- 112 pages
From €3697EUR$4,250USD£3,203GBP
From €2818EUR$3,240USD£2,442GBP
€3131EUR$3,600USD£2,713GBP
From €2505EUR$2,880USD£2,170GBP
€3131EUR$3,600USD£2,713GBP
- Report
- June 2020
- 114 pages
From €3697EUR$4,250USD£3,203GBP
From €2818EUR$3,240USD£2,442GBP
€3131EUR$3,600USD£2,713GBP
- Report
- May 2020
- 112 pages
From €3697EUR$4,250USD£3,203GBP
- Report
- January 2021
- 77 pages
From €1526EUR$1,754USD£1,322GBP
€1695EUR$1,949USD£1,469GBP
From €1540EUR$1,770USD£1,334GBP
From €1540EUR$1,770USD£1,334GBP
- Report
- September 2020
- 71 pages
From €1566EUR$1,800USD£1,356GBP
- Report
- September 2020
- 206 pages
From €3479EUR$4,000USD£3,014GBP
- Report
- September 2020
- 84 pages
From €1566EUR$1,800USD£1,356GBP
From €2792EUR$3,210USD£2,419GBP
From €2792EUR$3,210USD£2,419GBP
From €3471EUR$3,990USD£3,007GBP
Lymphoma encompasses a variety of blood cancers of the lymphatic system. Non-Hodgkin’s Lymphoma (NHL) for example, is diagnosed in over 100,000 every year in the US and EU combined. An array of expert reports in our Lymphoma Section enable you to investigate drug development strategies and market trends for NHL, Hodgkin’s Lymphoma, Skin Lymphoma, T-Cell Lymphoma, Indolent Lymphoma and other variants. Investigate key issues such as licensing, R&D, industry alliances, generic drugs (rituximab, bortezomib, doxorubicin, bleomycin, vinblastine, etc.) and the activities of major pharmaceutical players such as Bristol-Myers Squibb, GlaxoSmithKline, Hoffmann-La Roche, and Sanofi-Aventis. Show Less Read more
